Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review
Abstract
:1. Introduction
1.1. Chemical Properties
1.2. Sources of Exposure
1.3. Routes of Exposure
1.4. Toxicokinetics
1.5. Health Effects
1.6. Evidence Concerning Carcinogenicity
1.7. Exposure Thresholds
1.8. Study Rationale
2. Materials and Methods
2.1. Overview of Study Design
2.2. PECO
2.3. Data Streams
2.4. Literature Search
2.5. Human Toxicology Studies
2.6. Animal and Mechanistic Toxicology Studies
2.7. Inclusion/Exclusion Criteria
- Studies on poisoning and overdose were excluded, because it is likely that these effects would require a much higher dose than potential carcinogenic doses;
- Studies not involving mammalian species were excluded because of their doubtful applicability to humans;
- Studies in which exposure to antimony compounds is established through unnatural routes, such as intramuscular (IM)/subcutaneaous (SC)/ and intraperitoneal (IP) injection have questionable relevance;
- Studies on anticarcinogenic effects in cancer cells were excluded as one single molecule may enhance malignant transformation of healthy cells as well as inhibit the proliferation and growth of tumor cells [19], for instance consider the possibility that a certain compound induces mutations and at the same time inhibits angiogenesis.
2.8. Study Selection
2.8.1. Human Toxicology Studies
2.8.2. Animal Toxicology Studies
2.9. Data Extraction
2.10. Critical Appraisal: Study Quality and Risk of Bias (ROB) Assessment
2.11. Evidence Integration
3. Results
3.1. Data Extraction
3.1.1. Human Toxicology Studies
3.1.2. Animal Toxicology Studies
3.2. Critical Appraisal: Study Quality and Risk of Bias (ROB) Assessment
3.2.1. Human Toxicology Studies
- Individual studies involved different industries (metal mining vs. metal refinery vs. glass production);
3.2.2. Animal Toxicology Studies
Antimony Trioxide
Antimony Trichloride
Antimony Potassium Tartrate (APT)
Antimony Ore Concentrate (mostly Stibnite, Sb2S3)
4. Discussion
4.1. Evidence Integration
4.1.1. Carcinogenicity in Workers
Inhalation, ingestion, and dermal contact
Summary
4.1.2. Carcinogenicity in Animals
Inhalation
Ingestion
Dermal contact
Summary
4.1.3. Carcinogenicity Based on Mechanistic or Other Relevant Studies
4.2. Occupational Health Risk Assessment
4.3. Study Limitations
4.4. Suggestions for Further Research
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Hazardous Substances Data Bank. Available online: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB (accessed on 8 September 2018).
- Verdugo, M.; Ruiz Encinar, J.; Costa-Fernández, J.M.; Menendez-Miranda, M.; Bouzas-Ramos, D.; Bravo, M.; Quiroz, W. Study of conformational changes and protein aggregation of bovine serum albumin in presence of Sb(III) and Sb(V). PLoS ONE 2017, 12, e0170869. [Google Scholar] [CrossRef]
- Clemente, R. Antimony. In Heavy Metals in Soils; Alloway, B.J., Ed.; Springer: Dordrecht, The Netherlands, 2013; Volume 22, pp. 497–506. ISBN 978-94-007-4469-1. [Google Scholar]
- Wingren, G.; Axelson, O. Epidemiologic studies of occupational cancer as related to complex mixtures of trace elements in the art glass industry. Scand. J. Work Environ. Health 1993, 19, 95–100. [Google Scholar]
- Wingren, G.; Axelson, O. Mortality in the Swedish glassworks industry. Scand. J. Work Environ. Health 1987, 13, 412–416. [Google Scholar] [CrossRef]
- Agency for Toxic Substances and Disease Registry (ACGIH), U.S. Public Health Service. Toxicological Profile for Antimony and Compounds; Agency for Toxic Substances and Disease Registry (ACGIH), U.S. Public Health Service: Washington, DC, USA, 2017.
- Centers for Disease Control (CDC). National Biomonitoring Program: Biomonitoring Summary. Available online: http://www.cdc.gov/biomonitoring/Antimony_BiomonitoringSummary.html 2013 (accessed on 8 September 2018).
- Sundar, S.; Chakravarty, J. Antimony toxicity. Int. J. Environ. Res. Public Health 2010, 7, 4267–4277. [Google Scholar] [CrossRef] [PubMed]
- National Toxicology Program (NTP), N.I. of E.H.S. (NIEHS), U.S. Department of Health and Human Services. Report on Carcinogens Monograph on Antimony Trioxide; National Institutes of Health, HHS: Bethesda, MD, USA, 2017.
- Garg, S.P.; Singh, I.S.; Sharma, R.C. Long term lung retention studies of 125Sb aerosols in humans. Health Phys. 2003, 84, 457–468. [Google Scholar] [CrossRef] [PubMed]
- Environment and Climate Change. Health Canada. Draft Screening Assessment—Antimony Containing Substances; Environment and Climate Change. Health Canada: Ottawa, ON, Canada, 2018.
- McCallum, R.I. Occupational exposure to antimony compounds. J. Environ. Monit. 2005, 7, 1245–1250. [Google Scholar] [CrossRef] [PubMed]
- Gebel, T. Arsenic and antimony: Comparative approach on mechanistic toxicology. Chem. Biol. Interact. 1997, 107, 131–144. [Google Scholar] [CrossRef]
- De Boeck, M. Cobalt and antimony: Genotoxicity and carcinogenicity. Mutat. Res. /Fundam. Mol. Mech. Mutagenesis 2003, 533, 135–152. [Google Scholar] [CrossRef]
- International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Antimony Trioxide and Antimony Trisulfide; IARC: Lyon, France, 1989; Volume 47, pp. 291–305. [Google Scholar]
- National Toxicology Program (NTP), National Institutes of Environmental Health Sciences (NIEHS), U.S. Department of Health and Human Services. NTP Technical Report on the Toxicology and Carcinogenesis Studies of Antimony Trioxide (CAS No. 1309-64-4) in Wistar Han [Crl:WI (Han)] Rats and B6C3F1/N Mice (Inhalation Studies); U.S. Department of Health and Human Services: Washington, DC, USA, 2017; 303p.
- American Conference of Governmental Industrial Hygienists (ACGIH). TLVs and BEIs Based on the Documentation of the Threshold Limit Values for Chemical Substances and Physical Agents & Biological Indices; Association Advancing Occupational and Environmental Health: Cincinnati, OH, USA, 2018.
- Schaefer, H.R.; Myers, J.L. Guidelines for performing systematic reviews in the development of toxicity factors. Regul. Toxicol. Pharmacol. 2017, 91, 124–141. [Google Scholar] [CrossRef]
- Boffetta, P. Carcinogenicity of trace elements with reference to evaluations made by the International Agency for Research on Cancer. Scand. J. Work Environ. Health 1993, 19, 67–70. [Google Scholar]
- Gurnani, N.; Sharma, A.; Talukder, G. Cytotoxic effects of antimony trichloride on mice in vivo. Cytobios 1992, 70, 131–136. [Google Scholar] [PubMed]
- Watt, W.D. Chronic Inhalation Toxicity of Antimony Trioxide, Validation of the TLV; Wayne State University: Detroit, MI, USA, 1983. [Google Scholar]
- Sweeney, M.H.; Walrath, J.; Waxweiler, R.J. Mortality among retired fur workers. Dyers, dressers (tanners) and service workers. Scand. J. Work Environ. Health 1985, 11, 257–264. [Google Scholar] [CrossRef] [PubMed]
- Wingren, G.; Englander, V. Mortality and cancer morbidity in a cohort of Swedish glassworkers. Int. Arch. Occup. Environ. Health 1990, 62, 253–257. [Google Scholar] [CrossRef] [PubMed]
- Gerhardsson, L.; Brune, D.; Nordberg, G.F.; Wester, P.O. Multielemental assay of tissues of deceased smelter workers and controls. Sci. Total Environ. 1988, 74, 97–110. [Google Scholar] [CrossRef]
- Gerhardsson, L.; Nordberg, G.F. Lung cancer in smelter workers—Interactions of metals as indicated by tissue levels. Scand. J. Work Environ. Health 1993, 19 (Suppl. 1), 90–94. [Google Scholar] [PubMed]
- Zhang, C.; Li, P.; Wen, Y.; Feng, G.; Liu, Y.; Zhang, Y.; Xu, Y.; Zhang, Z. The promotion on cell growth of androgen-dependent prostate cancer by antimony via mimicking androgen activity. Toxicol. Lett. 2018, 288, 136–142. [Google Scholar] [CrossRef]
- Kotsopoulos, J.; Sukiennicki, G.; Muszyńska, M.; Gackowski, D.; Kąklewski, K.; Durda, K.; Jaworska, K.; Huzarski, T.; Gronwald, J.; Byrski, T.; et al. Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: An exploratory study. Cancer Causes Control 2012, 23, 1065–1074. [Google Scholar] [CrossRef]
- Rossi, F.; Acampora, R.; Vacca, S.; Maione, S.; Matera, M.G.; Servodio, R.; Marmo, E. Prenatal and postnatal antimony exposure in rats: Effect on vasomotor reactivity development of pups. Teratog. Carcinog. Mutagen. 1987, 7, 491–496. [Google Scholar] [CrossRef]
- Sunderman, F.W.; McCully, K.S. Carcinogenesis tests of Nickel Arsenides, Nickel Antimonide, and Nickel Telluride in rats. Cancer Investig. 1983, 1, 469–474. [Google Scholar] [CrossRef]
- Dieter, M.P.; Jameson, C.W.; Elwell, M.R.; Lodge, J.W.; Hejtmancik, M.; Grumbein, S.L.; Ryan, M.; Peters, A.C. Comparative toxicity and tissue distribution of antimony potassium tartrate in rats and mice dosed by drinking water or intraperitoneal injection. J. Toxicol. Environ. Health 1991, 34, 51–82. [Google Scholar] [CrossRef]
- Dieter, M. Toxicity Studies of Antimony Potassium Tartrate (Cas No.: 28300-74-5) in F344/N Rats and B6C3F1 Mice (Drinking Water and Intraperitoneal Injection Studies); NIH: Bethesda, MD, USA, 1992; 70p. [Google Scholar]
- Gurnani, N.; Sharma, A.; Talukder, G. Comparison of clastogenic effects of antimony and bismuth as trioxides on mice in vivo. Biol. Trace Elem. Res. 1993, 37, 281–292. [Google Scholar] [CrossRef] [PubMed]
- Kirkland, D.; Whitwell, J.; Deyo, J.; Serex, T. Failure of antimony trioxide to induce micronuclei or chromosomal aberrations in rat bone-marrow after sub-chronic oral dosing. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2007, 627, 119–128. [Google Scholar] [CrossRef] [PubMed]
- Gurnani, N.; Sharma, A.; Talukder, G. Comparison of the clastogenic effects of antimony trioxide on micein vivo following acute and chronic exposure. Biometals 1992, 5, 47–50. [Google Scholar] [CrossRef] [PubMed]
- Jones, R. Survey of antimony workers: Mortality 1961–1992. Occup. Environ. Med. 1994, 51, 772–776. [Google Scholar] [CrossRef] [PubMed]
- Jones, S.; Atkin, P.; Holroyd, C.; Lutman, E.; Vives i Batlle, J.; Wakeford, R.; Walker, P. Lung cancer mortality at a UK tin smelter. Occup. Med. 2007, 57, 238–245. [Google Scholar] [CrossRef] [PubMed]
- Gerhardsson, L.; Brune, D.; Nordberg, G.F.; Wester, P. Antimony in lung, liver and kidney tissue from deceased smelter workers. Scand. J. Work Environ. Health 1982, 8, 201–208. [Google Scholar] [CrossRef]
- Schnorr, T.M.; Steenland, K.; Thun, M.J.; Rinsky, R.A. Mortality in a cohort of antimony smelter workers. Am. J. Ind. Med. 1995, 27, 759–770. [Google Scholar] [CrossRef]
- Finkelstein, M.; Boulard, M.; Wilk, N. Increased risk of lung cancer in the melting department of a second Ontario (Canada) steel manufacturer. Am. J. Ind. Med. 1991, 19, 183–194. [Google Scholar] [CrossRef]
- Checkoway, H.; Pearce, N.; Kriebel, D. Overview of Study Designs. In Research Methods in Occupational Epidemiology; Oxford University Press: New York, NY, USA, 2004; pp. 59–73. [Google Scholar]
- Groth, D.H.; Stettler, L.E.; Burg, J.R.; Busey, W.M.; Grant, G.C.; Wong, L. Carcinogenic effects of antimony trioxide and antimony ore concentrate in rats. J. Toxicol. Environ. Health 1986, 18, 607–626. [Google Scholar] [CrossRef]
- Ainsworth, N.; Cooke, J.A.; Johnson, M.S. Behavior and toxicity of antimony in the short-tailed field vole (Microtus agrestis). Ecotoxicol. Environ. Saf. 1991, 21, 165–170. [Google Scholar] [CrossRef]
- Elliott, B.M.; Mackay, J.M.; Clay, P.; Ashby, J. An assessment of the genetic toxicology of antimony trioxide. Mutat. Res. /Genet. Toxicol. Environ. Mutagen. 1998, 415, 109–117. [Google Scholar] [CrossRef]
- Schroeder, H.A.; Kanisawa, M. Life term studies on the effect of trace elements on spontaneous tumors in mice and rats. Cancer Res. 1969, 29, 892–895. [Google Scholar]
- Schroeder, H.A.; Mitchener, M.; Nason, A.P. Zirconium, Niobium, Antimony, Vanadium and Lead in rats: Life term studies. J. Nutr. 1970, 100, 59–68. [Google Scholar] [CrossRef] [PubMed]
- Poon, R.; Chu, I.; Lecavalier, P.; Valli, V.E.; Foster, W.; Gupta, S.; Thomas, B. Effects of antimony on rats following 90-day exposure via drinking water. Food Chem. Toxicol. 1998, 36, 21–35. [Google Scholar] [CrossRef]
- Newton, P.E.; Bolte, H.F.; Daly, I.W.; Pillsbury, B.D.; Terrjll, J.B.; Drew, R.T.; Arthur, R.B.D.J.; Sheldon, W.; Rubin, L.F. Subchronic and chronic inhalation toxicity of Antimony Trioxide in the rat. Fundam. Appl. Toxicol. 1994, 22, 561–576. [Google Scholar] [CrossRef]
- Grosskopf, C.; Schwerdtle, T.; Mullenders, L.H.F.; Hartwig, A. Antimony impairs nucleotide excision repair: XPA and XPE as potential molecular targets. Chem. Res. Toxicol. 2010, 23, 1175–1183. [Google Scholar] [CrossRef]
- Koch, B.; Maser, E.; Hartwig, A. Low concentrations of antimony impair DNA damage signaling and the repair of radiation-induced DSB in HeLa S3 cells. Arch. Toxicol. 2017, 91, 3823–3833. [Google Scholar] [CrossRef]
- Hartwig, A.; Asmuss, M.; Ehleben, I.; Herzer, U.; Kostelac, D.; Pelzer, A.; Schwerdtle, T.; Bürkle, A. Interference by toxic metal Ions with DNA repair processes and cell cycle control. Mol. Mech. Environ. Health Perspect. 2002, 110, 797–799. [Google Scholar] [CrossRef] [Green Version]
- Mann, K.K.; Davison, K.; Colombo, M.; Colosimo, A.L.; Diaz, Z.; Padovani, A.M.S.; Guo, Q.; Scrivens, P.J.; Gao, W.; Mader, S.; et al. Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling. Toxicol. Lett. 2006, 160, 158–170. [Google Scholar] [CrossRef]
- Dieter, H. Antimony in drinking water. In Background Document for Development of WHO Guidelines for Drinking-Water Quality; World Health Organisation (WHO): Geneva, Switzerland, 2003. [Google Scholar]
- Tarazona, J.V.; Court-Marques, D.; Tiramani, M.; Reich, H.; Pfeil, R.; Istace, F.; Crivellente, F. Glyphosate toxicity and carcinogenicity: A review of the scientific basis of the European Union assessment and its differences with IARC. Arch. Toxicol. 2017, 91, 2723–2743. [Google Scholar] [CrossRef] [Green Version]
- Guo, J.; Su, L.; Zhao, X.; Xu, Z.; Chen, G. Relationships between urinary antimony levels and both mortalities and prevalence of cancers and heart diseases in general US population, NHANES 1999–2010. Sci. Total Environ. 2016, 571, 452–460. [Google Scholar] [CrossRef] [PubMed]
- Gebel, T. Suppression of arsenic-induced chromosome mutagenicity by antimony. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 1998, 412, 213–218. [Google Scholar] [CrossRef]
Compound Name | Chemical Formula | CAS-Number |
---|---|---|
Trivalent Positive (+III) | ||
antimony trioxide | Sb2O3 | 1309-64-4 |
antimony trisulfide | Sb2S3 | 1345-04-6 |
sodium stibogluconate | C12H20O17Sb2.3Na9H2O | 16037-91-5 |
antimony potassium tartrate | C8H4K2O12Sb2 | 28300-74-5 |
antimony trifluoride | SbF3 | 7783-56-4 |
antimony triiodide | SbI3 | 7790-44-5 |
antimony acetate | Sb(CH3COO)3 | 6923-52-0 |
antimony trichloride | SbCl3 | 10025-91-9 |
Trivalent Negative (−III) | ||
stibine | SbH3 | 7803-52-3 |
Elemental (0) | ||
elemental antimony | Sb | 7440-36-0 |
Pentavalent Positive (+V) | ||
antimony pentafluoride | SbF5 | 7783-70-2 |
antimony pentachloride | SbCl5 | 7647-18-9 |
Review Question: Population, Exposure, Comparison, and Outcome (PECO) (Table 3) | |||||
---|---|---|---|---|---|
Literature Review | |||||
Human Toxicology | Animal Toxicology | ||||
Pubmed | ToxNet | Pubmed | ToxNet | ||
Development of search terms | Development of search terms | Development of search terms | Development of search terms | ||
Development of Inclusion/Exclusion criteria | Development of Inclusion/Exclusion criteria | ||||
Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | ||
Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | ||
Articles excluded (no original data) | Articles excluded (no original data) | Articles excluded (no original data) | Articles excluded (no original data) | ||
Additional search with new search terms | Additional search with new search terms | ||||
Independent selection of articles by both reviewers | Independent selection of articles by both reviewers | ||||
Solving discrepancies between both reviewers | Solving discrepancies between both reviewers | ||||
Articles excluded (no original data) | Articles excluded (no original data) | ||||
Eliminating duplicate articles | Eliminating duplicate articles | ||||
Final pool of Human Toxicology studies | Final pool of Animal Toxicology studies | ||||
Data extraction (Table 4) | Data extraction (Table 5) | ||||
Quality and Risk of Bias (ROB) assessment of individual studies (Supplementary Material Table S5) | Quality and Risk of Bias (ROB) assessment of individual studies (Supplementary Material Table S6) | ||||
Human Exposure Evidence Integration and Evidence Level | Animal Exposure Evidence Integration and Evidence Level | ||||
Mechanistic and other relevant elements | |||||
Occupational health risk assessment | |||||
Suggestions for further research | |||||
Study limitations | |||||
General Evidence Integration and Conclusion |
Population |
Workers or occupationally exposed people, including possibly sensitive subgroups |
Exposure |
Exposure to antimony and antimony compounds (all substances containing antimony), through all possible exposure routes (dermal, inhalation and oral ingestion): |
- Elemental antimony; |
- Trivalent antimony (III) and species: Antimony trioxide, antimony trisulfide, antimony trifluoride, antimony trichloride, antimony tribromide, antimony triiodide, antimony potassium tartrate,… |
- Pentavalent antimony (V) and species: Antimony pentafluoride, antimony pentachloride,… |
- Trivalent negative antimony (-III) and species. |
Comparison |
Non-exposure or exposure beneath threshold that produces critical effect |
Outcome |
Development of any type of premalignant lesion, cancer, or malignancy |
Reference | Industry, Occupation, Exposure | Sample Characteristics | Sample Size (N) | Time period | Study Type | Dose of Exposure | Duration of Exposure | Findings |
---|---|---|---|---|---|---|---|---|
Gerhardsson 1982 [37] | Metal smelting and refinery (Sb species not specified) | Cases: deceased men in northern Sweden, and who died during the period 1976- 1978, divided into 3 groups (I: death caused by malignancy, II: death caused by cardiovascular disease III: death from other causes); Controls: age-matched men from a town 50 km from the factory | Cases: 40 (I: 15, II: 17, III: 8); Controls: 11 | Before 1978 (death 1976–1978) | Case-control | Not measured, instead tissue concentrations were measured | Duration of employment, interindividual differences. I: 30,9y +- 7,1; II: 32,5 +- 8,2; III: 28,9 +- 10 | Antimony amounts in lung tissue of deceased workers were significantly higher than in the reference group (p < 0.001). They did not differ significantly between worker groups. |
Sweeney 1985 [22] | Fur workers (Sb species not specified) | Subjects: pensioned fur dressers, compared to Standardized Mortality Ratios (SMR) in the US and in New York City (NYC) | 168 | Before 1977 | Retrospective occupational cohort | Not measured | No data | SMR’s for gross mortality are 118 and 111 (compared to US and NYC rates). Increased risk of death from all malignancies combined (SMR 184 (US) and 151 (NYC), p < 0.05), which reflected the significantly higher than expected risk from lung cancer (SMR 232, p < 0.05). Mortality from colorectal cancer, as well as from nonmalignant respiratory diseases, was also slightly elevated (not significant). |
Wingren 1987 [5] | Glassworks (Sb species not specified) | Subjects: glassworks employees. Referents: rural referents (farmers, forestry workers,…) | Subjects: 887; Referents: 4611 | 1950–1982 | Retrospective occupational cohort | Not measured | Duration of employment | OR for total cancer was 1.3 (90% CI 1.02–1.4), OR for lung cancer 1.9 (90% CI 1.1–2.5), OR for stomach cancer was 1.6 (90% CI 1.1–2.0), OR for colon cancer was 1.7 (90% CI 1.04–2.5). OR for cancer were highest in glassblowers. |
Wingren 1990 [23] | Glassworks (Sb species not specified) | Subjects: male art glass workers, compared to expected national and county mortality rates | 625 | 1964–1985 | Retrospective occupational cohort | Not measured | At least one month, average exposure per person 15,6 years; 9151 person years at risk | Compared to national and county death rates, a moderate increase in total cancer deaths was observed (not significant; 26 observed cases vs. 22.3 and 18.9 expected from national and county death rates, respectively). Particularly noted for lung cancer, (6 observed cases vs. 4.2 (p > 0,1) and 2.5 (p < 0,1) expected, respectively), colon cancer (4 observed cases vs. 1.6 expected, not significant), cancer of the pharynx (2 observed cases vs. 0.2 and 0.1 expected, p < 0.05 for both), and prostate (4 observed cases vs. 3.0 and 2.4 expected, not significant). A correlation with duration of exposure was seen. |
Finkelstein 1991 [39] | Steel manufacturing (Sb species not specified) | Subjects: deceased workers at an electric arc steel making operation, compared to expected provincial mortality rates | 335 | Deceased before 1989 | Retrospective occupational cohort | Below 10% of TLV for antimony | Ever worked | Eight of thirty men who had ever worked in the pouring pit area died of lung cancer (PMR=provincial mortality rate 276; p ≤ 0.01); non-significant excess mortality for lung cancer among other melting department employees (PMR 145, p = 0.1); excess mortality as well for gallbladder cancer (PMR 1000, p = 0.04). There was a significant correlation between lung cancer risk and duration of exposure. |
Gerhardsson 1993 [25] | Metal smelting/refinery (antimony sulfides and oxides) | Cases: deceased male smelter workers. Controls: 15 rural and 10 urban controls. | 85 | Before late 1970’s | Case-control | Not measured | 26 to 32 years | An 11-fold higher concentration of Sb in lungs of smelter workers was seen, not associated with higher incidence of lung cancer (compared to non-lung cancer smelter workers or rural or urban controls). |
Wingren 1993 [4] | Glassworks (Sb species not specified) | Subjects: glassworks employees. Referents: rural referents (farmers, forestry workers,…) | Subjects: 887; Referents: 4611 | 1950–1982 | Retrospective occupational cohort | Qualitatively stratified (none, low or high), not measured | Duration of employment, interindividual differences | OR (with 90% CI) for colon cancer were correlated with exposure: no exposure to antimony 1.4 (0.6–3.3) low exposure 1.8 (0.8–13.8) high exposure 5.0 (2.6–9.6); no excess risk for lung cancer and a decrease in stomach cancer risk were seen (no significance level reported). |
Jones 1994 [35] | Metal smelting/refinery (antimony oxides) | Subjects: antimony workers, compared to expected national and county death rates | 525 | Appr. 1940–1992 (study enrollment and follow-up period); split into two groups (before and after 1961) | Retrospective occupational cohort | Average levels of air contamination: 0,0005–0,11 mg/m3 | At least 3 months | An excess of all neoplasm mortality in antimony workers (69 vs 54.7 expected, p < 0.07) was seen, attributable to excess lung cancer mortality (37 vs. 23.9 expected, p = 0.016). This excess was not observed for workers recruited after 1/1/1961. |
Schnorr 1995 [38] | Antimony smelting (Sb species not specified) | Antimony smelter workers of predominantly hispanic ancestry, compared to national and ethnic specific death rates | 1014 (Hispanics: 923; white Texans: 91) | 1937–1971 (employment and follow-up period)) | Retrospective occupational cohort | Eight hour TWA for Sb exposure in 1975: mean 0,551 mg/m3 (range 0,110–2,0); in 1976 mean 0,747 mg/m3 (range 0,05–6,2) | At least 3 months, 33,773 person years at risk, of which 6.8 years employment per person on average | Overall cancer mortality (SMR 0.88; 95% CI 0.72–1.06) compared to US white mortality rates was diminished. This was expected among the Hispanic subgroup studied. Standardized Mortality Ratios (SMR) for lung cancer were (95% CI): 0.75 (0.51–1.07) and SMR (90% CI) 1.39 (1.01–1.88) relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively. An increase with duration of employment was seen. A significant excess in mortality was observed for cancers of the liver, biliary tract, and gall bladder (SMR 3.17; 95% CI 1.27–6.52 and SMR 1.58; 95% CI 0.57–3.44 relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively). Stomach cancer was elevated, but not significantly (SMR 1.49; 95% CI 0.71–2.74 and SMR 1.24; 95% CI 0.50–2.55 relative to U.S. white male mortality rates and Texas ethnic-specific mortality rates, respectively) |
Jones 2007 [36] | Metal smelting/refinery (Sb species not specified) | Subjects: 1462 male workers at a former tin smelter compared to expected national death rates | 1462 | 1972–1991, with back-extrapolation of expsoures until 1937 | Retrospective occupational cohort | 1972–1991: 0,37 mg/m3 (0,001–2,7); extrapolation of exposure data to 3 different scenarios (A, B, C). scenario A: 0,59 (0,003–3,3); scenario B 0,62 (0,003–3,7); scenario C 0,63 (0,003–4,7) | 35 942 person-years at risk | Weighted gradients (assuming that the resulting excess relative risk of lung cancer declines with time since exposure and attained age) and unweighted gradients were calculated for the relationship between Antimony exposure and lung cancer risk. None of the unweighted gradients were significant (significance level 0.05), whereas all of the calculated weighted gradients were significant: A, Sb weighted: 1.66 (0.56, 3.77 p = 0.004); B Sb weighted: 1.18 (0.28, 3.08 p = 0.013); C Sb weighted 1.20 (0.35, 2.09 p = 0.016)). |
Animal Studies - Inhalation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Reference | Antimony Compound | Study Animal and Sex (M: Male, F: Female) | Sample Size | Dose of Exposure | Duration of Exposure | Examinations Relevant to Cancer Development Assessment | Principal Findings | LOAEL/NOAEL | Notes |
Watt 1983 [21] | Antimony trioxide | CDF rats (only F) | 13, 17 and 18 per exposure group, respectively | 0, 1.6, 4.2 mg/m3 | 1 year/2 years | Unknown, data extracted from NTP report | Scirrhous lung carcinoma significantly increased in highest exposure group (p < 0.01); Squamous cell lung carcinoma not significantly increased; Alveolar/bronchiolar lung adenoma: not significantly increased. Significantly increased potential preneoplastic* lesions in all exposure groups: foci of fibrosis, lungs grossly mottled; pneumocyte hyperplasia; increases in incidence of multinucleated giant cells in exposed groups (no p value reported). | LOAEL for potential preneoplastic lung lesions (hyperplasia, fibrosis, grossly mottled lungs): 1.6 mg/m3 TWA and LOAEL for lung carcinoma: 4.2 mg/m3 TWA | * interpretation in NTP 2017, authors didn’t make statement about preneoplastic lesions; calculations of significance based on NTP 2017 |
Groth 1986 [41] | Antimony trioxide | Albino Wistar Han rats (M/F) | 90 per sex per exposure group | 0 and 45 or 46 mg/m3 (range 0-91 mg/m3) | 7 hours/day, 5 days/week during 71–73 weeks with intermediate sacrifice at 6, 9 and 12 months (5 per sex per group) | Full necropsy | No lung neoplasms in male rats. Significant increase in lung neoplasms in exposed female rats: total 19/89 vs. 0/89 (p < 0.001); Squamous cell carcinoma 9/89 vs. 0/89 (p < 0.01); Scirrhous carcinoma 5/89 vs. 0/89 (p < 0.05); Bronchioalveolar Adenoma 11/89vs 0/89 (p < 0.001). In females, histopathologic lung changes (not quantified): increase in dense particles aggregates, alveolar wall thickening consisting of interstitial fibrosis and alveolar cell-wall hypertrophy and hyperplasia; sometimes cuboidal and columnar cell metaplasia occurred from these foci. Foci containing cholesterol clefts were observed. Sometimes neoplasms arose from sites of interstitial fibrosis. In males: similar changes were seen, but less alveolar protein, less foci with cholesterol clefts, more metaplasia, more leukocytes, additionally eosinophilic material resembling amyloid No significant differences in other types of cancer. | LOAEL for lung neoplasms in female rats: 45 mg/m3 TWA | |
Antimony ore concentrate (principally stibnite, Sb2S3) | Albino Wistar Han rats (M/F) | 90 per sex per exposure group | 0 and 36 or 40 mg/m3 (range 0 -191) | 7 hours/day, 5 days/week during 71–73 weeks with intermediate sacrifice at 6, 9 and 12 months (5 per sex per exposure group) | Full necropsy | No lung neoplasms in male rats. Significant increase in lung neoplasms in exposed female rats vs. non-exposed rats: total 17/89 vs. 0/89 (p < 0,001); histopathology of the lungs in female and male rats exposed to Sb ore was qualitatively similar to that seen with the Sb2O3-exposed animals. The only differences for males were fewer particles and the presence of some birefringent particles, as well as granulomas in tracheobronchial lymph nodes. No significant differences in other types of cancer. | LOAEL for lung neoplasms in female rats: 36 mg/m3 TWA | ||
Newton 1994 [47] | Antimony trioxide | Fischer 344 rats (M/F) | 50 per sex per exposure group | 0, 0.25, 1, 5, and 25 mg/m3 | 6 h/day, 5 d/week for 13 weeks followed by 27 week postexposure period | Twice daily observation, gross post mortem examinations, histopathology of heart and airways | Survival equal. Elevated absolute and relative lung weights in two highest exposure groups. Leukemia (typical finding at this age in this species). Increase in lung lesions related to exposure: chronic interstitial inflammation, interstitial fibrosis, granulomatous inflammation in highest exposure groups, bronchiolar/alveolar hyperplasia, increase in alveolar macrophages (no calculation of significance). | NOAEL for carcinoma 25 mg/m3 | |
Antimony trioxide | Fischer 344 rats (M/F) | 65 per sex per exposure group | 0, 0.05, 0.5, and 5 mg/m3 | 6 h/day, 5 d/week for 52 weeks followed by 52 week postexposure period | Twice daily observation, gross post mortem examinations, histopathology of heart and airways | Increase in potential* preneoplastic lung lesions related to exposure: chronic interstitial inflammation in highest exposure group (p < 0.001), interstitial fibrosis (unclear if significant and at what exposure level), granulomatous inflammation (unclear if significant and at what exposure level), bronchiolar/alveolar hyperplasia (unclear if significant and at what exposure level), increase in alveolar/intra-alveolar/peribronchial macrophages (significant from 0.05 mg/m3). | NOAEL for carcinoma: 5 mg/m3; LOAEL for potential* preneoplastic lung lesions (increase in macrophages): 0.05 mg/m3 | * interpretation in NTP 2017, authors didn’t make statement about preneoplastic lesions; calculations of significance based on NTP 2017 | |
NTIS/NTP 2016 [16] | Antimony trioxide | Wistar Han Rats (M) | 50 per sex per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma or carcinoma: no significant difference; Alveolar/bronchiolar carcinoma: no significant difference; Alveolar/bronchiolar adenoma no significant difference. Significantly increased preneoplastic lesions (p < 0.01 for all exposed groups): lung alveolar epithelium hyperplasia; lung bronchiole epithelium hyperplasia. In adrenal gland: benign pheochromocytoma and adrenal medulla hyperplasia significantly increased in highest exposure group (both p < 0.05). | LOAEL for potential preneoplastic lung lesions (alveolar/bronchiolar epithelium hyperplasia): 3 mg/m3 exposure dose; NOAEL and LOAEL for adrenal medulla 10 and 30 mg/m3 | |
Wistar Han Rats (F) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 hper day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma or carcinoma: no significant difference; Alveolar/bronchiolar carcinoma: no significant difference; Alveolar/bronchiolar adenoma: significant increase in two highest exposure groups (p < 0.05). Significantly increased preneoplastic lesions: lung alveolar and brochiole epithelium hyperplasia (p < 0.01 for all exposed groups); In adrenal gland: benign and malignant pheochromocytoma (both p < 0.01) and medullar hyperplasia (p < 0.05) significantly increased in highest exposure group. | LOAEL for potential preneoplastic lung lesions (alveolar/bronchiolar epithelium hyperplasia): 3 mg/m3 exposure dose; NOAEL and LOAEL for adrenal medulla 10 and 30 mg/m3 | |||
Wistar Han Rats (M/F) | 5 per sex exposure group | 0, 3.75, 7.5, 15, 30, or 60 mg/m3 | 6 h plus T90 (12 minutes) per day, 5 d per week for 12 exposure days during a 16-day period | Full necropsy | Lung weights in 30 and 60 mg exposure group increased (p < 0.05). Incidences of chronic inflammation (increased numbers of alveolar macrophages, perivascular infiltrates of lymphocytes, monocytes, and neutrophils) were significantly increased in 30 and 60 mg exposure groups (p < 0.01). In areas of more intense inflammation, the alveolar architecture was sometimes obscured by inflammatory cells, cell debris, and fibrin, and was accompanied by Type 2 alveolar epithelial cell hyperplasia. No gross observations associated with exposure to antimony trioxide noted at necropsy. | NOAEL is 15 mg/m3 and LOAEL is 30 mg/m3 for chronic inflammation with hyperplasia and NOAEL and LOAEL for increased lung weights: 15 and 30 mg/m3 | |||
Wistar Han Rats (M/F) | 5 per sex per exposure group | 0,3,10, 30 mg/m3 | one year, 5 d per week, 6 h per day | MNPCE, MNNCE, PCE, and DNA Comet Assay | No increases in MNPCE, MNNCE, PCE or DNA damage in lung tissue samples or blood leukocytes were observed in male or female Wistar Han rats following exposure to antimony trioxide for 12 months. | NOAEL for MNPCE, PCE and DNA damage in lung tissue: 30 mg/m3 | MNNCE: micronucleated normochromatic erythrocytes; PCE: immature reticulocytes: sign of bone marrow toxicity | ||
B6C3F1/N mice (M) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma and Alveolar/bronchiolar carcinoma significantly increased among all exposure groups (p < 0.001). Significantly increased preneoplastic lesions: lung lymphocyte infiltration and alveolar epithelium hyperplasia (both p < 0.001, for all exposed groups). | LOAEL for lung carcinoma and preneoplastic lesions: 3 mg/m3 | |||
B6C3F1/N mice (F) | 50 per exposure group | 0,3,10, 30 mg/m3 | two years, 5 d per week, 6 h per day, with interim sacrifice at 6 and 12 months | Full necropsy | In lung tissue: Alveolar/bronchiolar adenoma and Alveolar/bronchiolar carcinoma significantly increased among all exposure groups (p < 0.01). Significantly increased preneoplastic lesions: lung lymphocyte infiltration (p <0.001 for all exposed groups) and alveolar/bronchiolar epithelium hyperplasia (both p < 0.01 for all exposed groups). Malignant lymphoma in whole body significantly increased (p < 0.05 for low exposure and p <0.001 for higher exposure); | LOAEL for lung carcinoma, preneoplastic lung lesions and malignant lymphoma: 3 mg/m3 | |||
B6C3F1/N mice (M/F) | 5 per sex per exposure group | 0, 3.75, 7.5, 15, 30, or 60 mg/m3 | 6 h plus T90 (12 minutes) per day, 5 d per week for 12 exposure days during a 16-day period. | Full necropsy | Relative lung weights were significantly increased in 60 mg/m3 males (p < 0.01) and in 15 mg/m3 females (p < 0.01); absolute and relative lung weights already were increased at 7.5 mg/m3 for males and females, respectively. In the larynx, there were significantly increased incidences of squamous metaplasia of the epiglottis from 30 mg/m3 on. No gross observations associated with exposure to antimony trioxide noted at necropsy. | LOAEL for increased absolute (M) and relative (F) lung weights; NOAEL is 3.75 mg/m3 | |||
B6C3F1/N mice (M/F) | 5 per sex per exposure group | 0,3,10, 30 mg/m3 | one year, 5 days per week, 6 hours per day | MNPCE, MNNCE, PCE, and DNA Comet Assay | Significant increases in MNNCE at highest exposure concentration (p < 0.001), and PCE in male (at 10 mg/m3, p < 0.001)) and female (at 30 mg/m3, p <0.01) mice. Increased levels of DNA damage in male 3 mg/m3 and female highest exposure group (both p <0.001) lung tissue samples, but not in peripheral blood leukocytes. | LOAEL (lung DNA damage): 3 mg/m3 | |||
Animal Studies - Ingestion | |||||||||
Reference | Antimony Compound | Study animal and sex (M: male, F: female) | Sample size | Dose of Exposure | Duration of exposure | Examinations relevant to cancer development assessment | Principal findings | LOAEL/NOAEL | Notes |
Kanisawa 1969 [44] | Antimony potassium tartrate (APT) | Swiss albino mice (M/F) of the Charles River Strain (CD-1) | 76 for Antimony exposure and 71 controls | 5 mcg/ml drinking water | Lifetime** | Sections of five tissues and gross tumors | Compared to controls, significant differences in the incidences of spontaneous tumors and malignant tumors did not appear. | NOAEL 5 mcg/mL drinking water | **(50% dead males: 582 days, 90% dead males: 651; 50% dead females: 576 days, 90% dead females: 742 d) |
Schroeder 1970 [45] | Antimony potassium tartrate (APT) | Long-Evans strain rats (M/F) | 51 male and 59 female rats (antimony group) and 52 male and 54 female rats (control group) | 5 ppm in drinking water | Lifetime** | Survival time and development of grossly visible tumors | Survival time reduced in antimony fed rats (on average 106 d less for male and 107 d less for females). No significant difference in macroscopic tumor development | LOAEL for increased mortality: 5 ppm drinking water | ** mean per sex: M 746 days (90% dead: 987 days) and F 797 days (90% dead 992 d) |
Ainsworth 1991 [42] | Antimony trioxide | Microtus agrestis (short tailed field vole) | According to exposure duration: 8, 10, 8, 8 and 12, 8 | 500 mg Sb/kg food; | 30, 40, 50, 60 d and 30+5 recovery, 30+10 recovery | Not explicitly stated | No obvious harmful effects: The appearance of the internal organs of voles receiving the 500 mg Sb/ kg diet was indistinguishable from that of the control voles. Wet and dry weights of the liver, kidney, and lungs of animals receiving the 500 mg Sb /kg diet were not significantly different from those of control animals. | NOAEL 500 mg/kg food dose | |
Antimony trioxide | Microtus agrestis (short tailed field vole) | 6 per exposure group p | 20000 mg Sb/kg food | 12 d | Not explicitly stated | Animals remained healthy. No histological changes compared to control group voles could be observed in the sections of liver and kidney examined by electron microscopy. | NOAEL 20,000 mg/kg food exposure monodose | ||
Gurnani 1992 (1)[32] | Antimony trioxide | Swiss albino mice (M/F) | 5 per exposure group | 0, 400, 666.67 and 1000 mg/kg body mass | 6, 12, 24 h | Chromosomal abberations: chromatid gaps, chromatid breaks, centric fusions and polyploidy in bone marrow cells | In the acute exposure groups, no clastogenic effects were seen. | NOAEL 1000 mg/kg body weight dose | |
Antimony trioxide | Swiss albino mice (only M) | 5 per exposure group | 0, 400, 666.67 and 1000 mg/kg body mass | 7, 14 and 21 d | Chromosomal abberations: chromatid gaps, chromatid breaks, centric fusions and polyploidy in bone marrow cells | In the 21d exposure groups, dose dependent chromosomal abberations were seen for both sexes (p < 0.001 for trend). The highest dose was lethal on day 20 of treatment. No relationship was seen with duration of exposure. | LOAEL for CA: 400 mg/kg body weight | ||
Gurnani 1992 (2)[20] | Antimony trichloride | Swiss albino mice | Unknown | Unknown, several | 6, 12, 24 h | Chromosomal abberations in bone marrow cells | Frequencies of chromosomal aberrations (DNA strand breaks principally) were directly related to the dose used and were significantly higher than the control.*** | Inference not possible based on abstract | *** data extracted from abstract |
Dieter 1992 [31] | Antimony potassium tartrate (APT) | Fischer 344 rats (M/F) | 5 per sex for each dose group | 0, 0.15, 0.30, 0.65, 1.25, and 2.5 mg/mL in drinking water or cumulative daily dose of 0, 16, 28, 59, 94, or 168 mg/kg | 14 d | Clinical signs, clinical pathology of several tissues, hematology tests | No clinical nor histopatholigical signs of APT Toxicity in none of the exposure groups | NOAEL of 168 mg APT/kg body weight | |
Antimony potassium tartrate (APT) | B6C3F1 mice (M/F) | 5 per sex for each dose group | 0, 0.30, 0.65, 1.25, 2.5, and 5.0 mg/mL or cumulative daily dose of 0, 59, 98, 174, 273, or 407 mg/kg | 14 d | Clinical signs, clinical pathology of several tissues, hematology tests | Effects were only seen in 407 mg/kg group: Clinical signs of toxicity: impaired weight gain, rough haircoat, emaciation, abnormal posture, hypoactivity, and decreased fecal material, consistent with avoidance of the APT-dosed water. Histopathological signs: in forestomach: necrosis, ulceration, inflammation and focal hyperplasia of squamous epithelium; in hepatocytes: centriblobular cytoplasmic vacuolization. | NOAEL of 273 mg APT/kg body weight, LOAEL for stomach squamaous epithelium hyperplasia: 407 mg APT/kg body weight | ||
Poon 1998 [46] | Antimony potassium tartrate (APT) | Sprague–Dawley Crl:CD (SD) rats (M/F) | 95 male and 95 female, divided in groups | groups: control (25), 0.5 ppm (15), 5 ppm (15), 50 ppm (15) and 500 ppm (25) | 90 d | Full Necropsy | No clinical signs of toxicity; A male rat in the highest dose group had a cirrhotic liver and a female rat in the lowest dose group had a nodular, fibrotic, spleen. Persistent dose-dependent histological changes in thyroid gland, perisistent dose dependent histological changes in liver (irreversible after 4 wk recovery period), very mild treatment-related changes in spleen developing predominantly in recovery period; changes in thymus in recovery period; minimal non-dose dependent changes in pituitary gland. | inference not possible based on paper | |
Elliott 1998 [43] | Antimony trioxide | CD-1 mice (M/F) | Not indicated | 5000 mg/kg Antimony Trioxide (single dose) OR 400, 666.67, 1000 mL/kg/day | single dose or 7, 14 and 21 d | Micronucleated Polychromatic Erythrocytes (MNPCE) | No difference in micronucleated polychromatic erythrocytes in both species; significant decrease in polychromatic erythrocytes in female mice for single dose study | NOAEL for MNPCE: 5000 mg/kg monodose or 1000 ml/kg repeated dose LOAEL for decrease in PCE: 5000 mg/kg in single dose | |
Antimony trioxide | Alderley Park Alpk: APfSD rats (only M) | Not indicated; per animal 2000 polychromatic erythrocytes and 1000 erythrocytes | 3200 or 5000 mg/kg | Single dose | Liver DNA repair assay | No significant differences | NOAEL for liver DNA repair: 1000 ml/kg | ||
Kirkland 2007 [34] | Antimony trioxide | Sprague–Dawley Crl:CD (SD) rats (M/F) | 6 per exposure group per sex | 1000 mg once and 250 or 500 or 1000 mg/kg food/day Sb2O3 and positive control CycloPhosphAmid 20 mg/kg once or vehicle controls | Single dose or 21 d | Micronuclei (MN) and chromosomal abberations (CA) | No clinical signs of toxicity. No difference in mitotic indexes between exposed groups and unexposed groups; chromosomal abberations in Sb2O3 treated groups were low (falling within normal ranges) and not significantly higher than in vehicle controls; Micronucleated polychromatic erythrocytes (MNPCE): % PCE not reduced in Sb2O3 treated groups as compared to vehicle control; MN frequencies in Sb2O3 exposed groups within normal ranges and not significantly different from vehicle control groups | NOAEL for MNPCE and CA: 1000 mg/kg food dose | |
Animal Studies - Dermal contact | |||||||||
Reference | Antimony Compound | Study animal and sex (M: male, F: female) | Sample size | Dose of Exposure | Duration of exposure | Examinations relevant to cancer development assessment | Principal findings | LOAEL/NOAEL | |
NTIS/NTP 2016 [16] | Antimony trioxide | B6C3F1/N mice (M/F) | 50 per sex per exposure group | 0,3,10, 30 mg/m3 | Two years, 5 d per week, 6 hper day, with interim sacrifice at 6 and 12 months | Skin histopathology | Significant increase in benign fibrous histiocytoma and fibrous histiocytoma/fibrosarcoma (p < 0.05 for both in highest exposure groups) in males; non significant increase in squamous cell metaplasia in females | LOAEL for male mice and NOAEL for female mice: 30 mg/m3 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saerens, A.; Ghosh, M.; Verdonck, J.; Godderis, L. Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review. Int. J. Environ. Res. Public Health 2019, 16, 4474. https://doi.org/10.3390/ijerph16224474
Saerens A, Ghosh M, Verdonck J, Godderis L. Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review. International Journal of Environmental Research and Public Health. 2019; 16(22):4474. https://doi.org/10.3390/ijerph16224474
Chicago/Turabian StyleSaerens, Anton, Manosij Ghosh, Jelle Verdonck, and Lode Godderis. 2019. "Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review" International Journal of Environmental Research and Public Health 16, no. 22: 4474. https://doi.org/10.3390/ijerph16224474
APA StyleSaerens, A., Ghosh, M., Verdonck, J., & Godderis, L. (2019). Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review. International Journal of Environmental Research and Public Health, 16(22), 4474. https://doi.org/10.3390/ijerph16224474